The DOI matches its Crossref record; 177 of the 177 references it cites were found in a registry or an index.
Advances in acute myeloid leukemia
Abstract
Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with historically high mortality rates. The standard of care treatment remained unchanged for decades; however, recent discoveries of molecular drivers of leukemogenesis and disease progression have led to novel therapies for AML. Ongoing research and clinical trials are actively seeking to personalize therapy by identifying molecular targets, discovering patient specific and disease specific risk factors, and identifying effective combinations of modalities and drugs. This review focuses on important updates in diagnostic and disease classifications that reflect new understanding of the biology of AML, its mutational heterogeneity, some important genetic and environmental risk factors, and new treatment options including cytotoxic chemotherapy, novel targeted agents, and cellular therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Arber, D. A., Orazi, A., Hasserjian, R., Thiele, J., Borowitz, M. J., Le Beau, M. M., Bloomfield, C. D., Cazzola, M., & Vardiman, J. W. (2016) · Blood · doi:10.1182/blood-2016-03-643544 · Cited by 10,119
Döhner, H., Estey, E., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., Dombret, H., Ebert, B. L., Fenaux, P., Larson, R. A., et al. (2017) · Blood · doi:10.1182/blood-2016-08-733196 · Cited by 5,775
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1976) · British Journal of Haematology · doi:10.1111/j.1365-2141.1976.tb03563.x · Cited by 5,602
Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia
The Cancer Genome Atlas Research Network (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301689 · Cited by 5,078
Age-related clonal hematopoiesis associated with adverse outcomes
Jaiswal, S., Fontanillas, P., Flannick, J., Manning, A., Grauman, P. V., Mar, B. G., Lindsley, R. C., Mermel, C. H., Burtt, N., Chavez, A., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408617 · Cited by 4,841
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Genomic classification and prognosis in acute myeloid leukemia
Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., Potter, N. E., Heuser, M., Thol, F., Bolli, N., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1516192 · Cited by 4,350
Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence
Genovese, G., Kähler, A. K., Handsaker, R. E., Lindberg, J., Rose, S. A., Bakhoum, S. F., Chambert, K., Mick, E., Neale, B. M., Fromer, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409405 · Cited by 3,531
Döhner, H., Estey, E. H., Amadori, S., Appelbaum, F. R., Büchner, T., Burnett, A. K., Dombret, H., Fenaux, P., Grimwade, D., Larson, R. A., et al. (2010) · Blood · doi:10.1182/blood-2009-07-235358 · Cited by 3,373
Döhner, H., Weisdorf, D. J., & Bloomfield, C. D. (2015) · New England Journal of Medicine · doi:10.1056/nejmra1406184 · Cited by 3,306
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207
BENNETT, J. M., CATOVSKY, D., DANIEL, M. T., FLANDRIN, G., GALTON, D. A. G., GRALNICK, H. R., & SULTAN, C. (1985) · Annals of Internal Medicine · doi:10.7326/0003-4819-103-4-620 · Cited by 2,926
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
DiNardo, C. D., Jonas, B. A., Pullarkat, V., Thirman, M. J., Garcia, J. S., Wei, A. H., Konopleva, M., Döhner, H., Letai, A., Fenaux, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2012971 · Cited by 2,900
Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease
Jaiswal, S., Natarajan, P., Silver, A. J., Gibson, C. J., Bick, A. G., Shvartz, E., McConkey, M., Gupta, N., Gabriel, S., Ardissino, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701719 · Cited by 2,683
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
Stone, R. M., Mandrekar, S. J., Sanford, B. L., Laumann, K., Geyer, S., Bloomfield, C. D., Thiede, C., Prior, T. W., Döhner, K., Marcucci, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614359 · Cited by 2,250
The World Health Organization (WHO) classification of the myeloid neoplasms
Vardiman, J. W., Harris, N. L., & Brunning, R. D. (2002) · Blood · doi:10.1182/blood-2002-04-1199 · Cited by 2,197
Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes
Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971
Miller, J. S., Soignier, Y., Panoskaltsis-Mortari, A., McNearney, S. A., Yun, G. H., Fautsch, S. K., McKenna, D., Le, C., Defor, T. E., Burns, L. J., et al. (2005) · Blood · doi:10.1182/blood-2004-07-2974 · Cited by 1,903
Age-related mutations associated with clonal hematopoietic expansion and malignancies
Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., Schmidt, H. K., Yellapantula, V., Miller, C. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3733 · Cited by 1,874
DiNardo, C. D., Pratz, K., Pullarkat, V., Jonas, B. A., Arellano, M., Becker, P. S., Frankfurt, O., Konopleva, M., Wei, A. H., Kantarjian, H. M., et al. (2019) · Blood · doi:10.1182/blood-2018-08-868752 · Cited by 1,825
Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia
Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.-T., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061094 · Cited by 1,813
Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia
Shlush, L. I., Zandi, S., Mitchell, A., Chen, W. C., Brandwein, J. M., Gupta, V., Kennedy, J. A., Schimmer, A. D., Schuh, A. C., Yee, K. W., et al. (2014) · Nature · doi:10.1038/nature13038 · Cited by 1,443
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML
Perl, A. E., Martinelli, G., Cortes, J. E., Neubauer, A., Berman, E., Paolini, S., Montesinos, P., Baer, M. R., Larson, R. A., Ustun, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902688 · Cited by 1,287
Dombret, H., Seymour, J. F., Butrym, A., Wierzbowska, A., Selleslag, D., Jang, J. H., Kumar, R., Cavenagh, J., Schuh, A. C., Candoni, A., et al. (2015) · Blood · doi:10.1182/blood-2015-01-621664 · Cited by 1,165
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Daver, N., Schlenk, R. F., Russell, N. H., & Levis, M. J. (2019) · Leukemia · doi:10.1038/s41375-018-0357-9 · Cited by 1,075
Konopleva, M., Pollyea, D. A., Potluri, J., Chyla, B., Hogdal, L., Busman, T., McKeegan, E., Salem, A. H., Zhu, M., Ricker, J. L., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0313 · Cited by 1,064
Schuurhuis, G. J., Heuser, M., Freeman, S., Béné, M.-C., Buccisano, F., Cloos, J., Grimwade, D., Haferlach, T., Hills, R. K., Hourigan, C. S., et al. (2018) · Blood · doi:10.1182/blood-2017-09-801498 · Cited by 1,041
Lancet, J. E., Uy, G. L., Cortes, J. E., Newell, L. F., Lin, T. L., Ritchie, E. K., Stuart, R. K., Strickland, S. A., Hogge, D., Solomon, S. R., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6112 · Cited by 1,025
Self-citationCastaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
Lindsley, R. C., Mar, B. G., Mazzola, E., Grauman, P. V., Shareef, S., Allen, S. L., Pigneux, A., Wetzler, M., Stuart, R. K., Erba, H. P., et al. (2015) · Blood · doi:10.1182/blood-2014-11-610543 · Cited by 991
Li, Y., Hermanson, D. L., Moriarity, B. S., & Kaufman, D. S. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.06.002 · Cited by 981
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Fernandez, H. F., Sun, Z., Yao, X., Litzow, M. R., Luger, S. M., Paietta, E. M., Racevskis, J., Dewald, G. W., Ketterling, R. P., Bennett, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904544 · Cited by 919
Sievers, E. L., Larson, R. A., Stadtmauer, E. A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J. M., Sherman, M. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3244 · Cited by 899
Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia
Wong, T. N., Ramsingh, G., Young, A. L., Miller, C. A., Touma, W., Welch, J. S., Lamprecht, T. L., Shen, D., Hundal, J., Fulton, R. S., et al. (2015) · Nature · doi:10.1038/nature13968 · Cited by 892
Coombs, C. C., Zehir, A., Devlin, S. M., Kishtagari, A., Syed, A., Jonsson, P., Hyman, D. M., Solit, D. B., Robson, M. E., Baselga, J., et al. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.07.010 · Cited by 866
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Assessment of Minimal Residual Disease in Standard-Risk AML
Ivey, A., Hills, R. K., Simpson, M. A., Jovanovic, J. V., Gilkes, A., Grech, A., Patel, Y., Bhudia, N., Farah, H., Mason, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507471 · Cited by 845
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis
Busque, L., Patel, J. P., Figueroa, M. E., Vasanthakumar, A., Provost, S., Hamilou, Z., Mollica, L., Li, J., Viale, A., Heguy, A., et al. (2012) · Nature Genetics · doi:10.1038/ng.2413 · Cited by 830
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Löwenberg, B., Ossenkoppele, G. J., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901409 · Cited by 828
Stilgenbauer, S., Eichhorst, B., Schetelig, J., Coutre, S., Seymour, J. F., Munir, T., Puvvada, S. D., Wendtner, C.-M., Roberts, A. W., Jurczak, W., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30019-5 · Cited by 805
TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes
Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O’Laughlin, M., Fulton, R. S., Wilson, R. K., Baty, J. D., Duncavage, E. J., Tandon, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605949 · Cited by 796
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
Jongen-Lavrencic, M., Grob, T., Hanekamp, D., Kavelaars, F. G., al Hinai, A., Zeilemaker, A., Erpelinck-Verschueren, C. A. J., Gradowska, P. L., Meijer, R., Cloos, J., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716863 · Cited by 786
Clonal Architecture of Secondary Acute Myeloid Leukemia
Walter, M. J., Shen, D., Ding, L., Shao, J., Koboldt, D. C., Chen, K., Larson, D. E., McLellan, M. D., Dooling, D., Abbott, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106968 · Cited by 775
Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults
Young, A. L., Challen, G. A., Birmann, B. M., & Druley, T. E. (2016) · Nature Communications · doi:10.1038/ncomms12484 · Cited by 692
Wei, A. H., Strickland, S. A., Hou, J.-Z., Fiedler, W., Lin, T. L., Walter, R. B., Enjeti, A., Tiong, I. S., Savona, M., Lee, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01600 · Cited by 692
Rücker, F. G., Schlenk, R. F., Bullinger, L., Kayser, S., Teleanu, V., Kett, H., Habdank, M., Kugler, C.-M., Holzmann, K., Gaidzik, V. I., et al. (2012) · Blood · doi:10.1182/blood-2011-08-375758 · Cited by 683
DiNardo, C. D., Tiong, I. S., Quaglieri, A., MacRaild, S., Loghavi, S., Brown, F. C., Thijssen, R., Pomilio, G., Ivey, A., Salmon, J. M., et al. (2020) · Blood · doi:10.1182/blood.2019003988 · Cited by 679
Petersdorf, S. H., Kopecky, K. J., Slovak, M., Willman, C., Nevill, T., Brandwein, J., Larson, R. A., Erba, H. P., Stiff, P. J., Stuart, R. K., et al. (2013) · Blood · doi:10.1182/blood-2013-01-466706 · Cited by 638
An introduction to chimeric antigen receptor (CAR) T‐cell immunotherapy for human cancer
Feins, S., Kong, W., Williams, E. F., Milone, M. C., & Fraietta, J. A. (2019) · American Journal of Hematology · doi:10.1002/ajh.25418 · Cited by 614
Taplitz, R. A., Kennedy, E. B., Bow, E. J., Crews, J., Gleason, C., Hawley, D. K., Langston, A. A., Nastoupil, L. J., Rajotte, M., Rolston, K. V., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00374 · Cited by 601
The urgent need to recover MHC class I in cancers for effective immunotherapy
Garrido, F., Aptsiauri, N., Doorduijn, E. M., Garcia Lora, A. M., & van Hall, T. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.12.007 · Cited by 585
Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age
Busque, L., Mio, R., Mattioli, J., Brais, E., Blais, N., Lalonde, Y., Maragh, M., & Gilliland, D. (1996) · Blood · doi:10.1182/blood.v88.1.59.59 · Cited by 543
Genomics of Acute Myeloid Leukemia Diagnosis and Pathways
Bullinger, L., Döhner, K., & Döhner, H. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2208 · Cited by 541
Cortes, J. E., Heidel, F. H., Hellmann, A., Fiedler, W., Smith, B. D., Robak, T., Montesinos, P., Pollyea, D. A., DesJardins, P., Ottmann, O., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0312-9 · Cited by 496
Gill, S., Tasian, S. K., Ruella, M., Shestova, O., Li, Y., Porter, D. L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S. A., et al. (2014) · Blood · doi:10.1182/blood-2013-09-529537 · Cited by 489
A No-Prophylaxis Platelet-Transfusion Strategy for Hematologic Cancers
Stanworth, S. J., Estcourt, L. J., Powter, G., Kahan, B. C., Dyer, C., Choo, L., Bakrania, L., Llewelyn, C., Littlewood, T., Soutar, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212772 · Cited by 472
Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes
Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02341 · Cited by 465
Hoelzer, D., Bassan, R., Dombret, H., Fielding, A., Ribera, J. M., & Buske, C. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw025 · Cited by 463
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation
Christopher, M. J., Petti, A. A., Rettig, M. P., Miller, C. A., Chendamarai, E., Duncavage, E. J., Klco, J. M., Helton, N. M., O’Laughlin, M., Fronick, C. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1808777 · Cited by 463
Kim, M. Y., Yu, K.-R., Kenderian, S. S., Ruella, M., Chen, S., Shin, T.-H., Aljanahi, A. A., Schreeder, D., Klichinsky, M., Shestova, O., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.013 · Cited by 459
Granfeldt Østgård, L. S., Medeiros, B. C., Sengeløv, H., Nørgaard, M., Andersen, M. K., Dufva, I. H., Friis, L. S., Kjeldsen, E., Marcher, C. W., Preiss, B., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0890 · Cited by 451
Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies
Bowman, R. L., Busque, L., & Levine, R. L. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.01.011 · Cited by 448
Ritchie, D. S., Neeson, P. J., Khot, A., Peinert, S., Tai, T., Tainton, K., Chen, K., Shin, M., Wall, D. M., Hönemann, D., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.154 · Cited by 443
de Lima, M., Giralt, S., Thall, P. F., de Padua Silva, L., Jones, R. B., Komanduri, K., Braun, T. M., Nguyen, H. Q., Champlin, R., & Garcia‐Manero, G. (2010) · Cancer · doi:10.1002/cncr.25500 · Cited by 427
Therapy-related myeloid neoplasms: when genetics and environment collide
McNerney, M. E., Godley, L. A., & Le Beau, M. M. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.60 · Cited by 419
Knorr, D. A., Ni, Z., Hermanson, D., Hexum, M. K., Bendzick, L., Cooper, L. J. N., Lee, D. A., & Kaufman, D. S. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0084 · Cited by 415
The Incidence of Leukemia, Lymphoma and Multiple Myeloma among Atomic Bomb Survivors: 1950–2001
Hsu, W.-L., Preston, D. L., Soda, M., Sugiyama, H., Funamoto, S., Kodama, K., Kimura, A., Kamada, N., Dohy, H., Tomonaga, M., et al. (2013) · Radiation Research · doi:10.1667/rr2892.1 · Cited by 409
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
Toffalori, C., Zito, L., Gambacorta, V., Riba, M., Oliveira, G., Bucci, G., Barcella, M., Spinelli, O., Greco, R., Crucitti, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0400-z · Cited by 401
Araki, D., Wood, B. L., Othus, M., Radich, J. P., Halpern, A. B., Zhou, Y., Mielcarek, M., Estey, E. H., Appelbaum, F. R., & Walter, R. B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.3826 · Cited by 400
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
Takahashi, K., Wang, F., Kantarjian, H., Doss, D., Khanna, K., Thompson, E., Zhao, L., Patel, K., Neelapu, S., Gumbs, C., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30626-x · Cited by 399
Gafter-Gvili, A., Fraser, A., Paul, M., Vidal, L., Lawrie, T. A., van de Wetering, M. D., Kremer, L. C., & Leibovici, L. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004386.pub3 · Cited by 383
Lambert, J., Pautas, C., Terré, C., Raffoux, E., Turlure, P., Caillot, D., Legrand, O., Thomas, X., Gardin, C., Gogat-Marchant, K., et al. (2019) · Haematologica · doi:10.3324/haematol.2018.188888 · Cited by 361
Casucci, M., Nicolis di Robilant, B., Falcone, L., Camisa, B., Norelli, M., Genovese, P., Gentner, B., Gullotta, F., Ponzoni, M., Bernardi, M., et al. (2013) · Blood · doi:10.1182/blood-2013-04-493361 · Cited by 357
Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia
Ehninger, A., Kramer, M., Röllig, C., Thiede, C., Bornhäuser, M., von Bonin, M., Wermke, M., Feldmann, A., Bachmann, M., Ehninger, G., et al. (2014) · Blood Cancer Journal · doi:10.1038/bcj.2014.39 · Cited by 355
Isocitrate dehydrogenase mutations in myeloid malignancies
Medeiros, B. C., Fathi, A. T., DiNardo, C. D., Pollyea, D. A., Chan, S. M., & Swords, R. (2017) · Leukemia · doi:10.1038/leu.2016.275 · Cited by 350
Maertens, J. A., Girmenia, C., Brüggemann, R. J., Duarte, R. F., Kibbler, C. C., Ljungman, P., Racil, Z., Ribaud, P., Slavin, M. A., Cornely, O. A., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dky286 · Cited by 348
Therapy-Related Myeloid Leukemia
Godley, L. A., & Larson, R. A. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.012 · Cited by 347
Hematopoietic stem cell transplantation for patients with AML in first complete remission
Cornelissen, J. J., & Blaise, D. (2016) · Blood · doi:10.1182/blood-2015-07-604546 · Cited by 346
Wandt, H., Schaefer-Eckart, K., Wendelin, K., Pilz, B., Wilhelm, M., Thalheimer, M., Mahlknecht, U., Ho, A., Schaich, M., Kramer, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60689-8 · Cited by 341
Pollyea, D. A., Bixby, D., Perl, A., Bhatt, V. R., Altman, J. K., Appelbaum, F. R., de Lima, M., Fathi, A. T., Foran, J. M., Gojo, I., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0002 · Cited by 320
Gillis, N. K., Ball, M., Zhang, Q., Ma, Z., Zhao, Y., Yoder, S. J., Balasis, M. E., Mesa, T. E., Sallman, D. A., Lancet, J. E., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30627-1 · Cited by 317
How I treat acute myeloid leukemia in the era of new drugs
DiNardo, C. D., & Wei, A. H. (2020) · Blood · doi:10.1182/blood.2019001239 · Cited by 290
Heuser, M., Ofran, Y., Boissel, N., Brunet Mauri, S., Craddock, C., Janssen, J., Wierzbowska, A., & Buske, C. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.018 · Cited by 284
Hulegårdh, E., Nilsson, C., Lazarevic, V., Garelius, H., Antunovic, P., Rangert Derolf, Å., Möllgård, L., Uggla, B., Wennström, L., Wahlin, A., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.23908 · Cited by 269
Röllig, C., Bornhäuser, M., Thiede, C., Taube, F., Kramer, M., Mohr, B., Aulitzky, W., Bodenstein, H., Tischler, H.-J., Stuhlmann, R., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8500 · Cited by 265
Kadia, T. M., Jain, P., Ravandi, F., Garcia‐Manero, G., Andreef, M., Takahashi, K., Borthakur, G., Jabbour, E., Konopleva, M., Daver, N. G., et al. (2016) · Cancer · doi:10.1002/cncr.30203 · Cited by 261
Chen, X., Xie, H., Wood, B. L., Walter, R. B., Pagel, J. M., Becker, P. S., Sandhu, V. K., Abkowitz, J. L., Appelbaum, F. R., & Estey, E. H. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3518 · Cited by 257
CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
Testa, U., Pelosi, E., & Frankel, A. (2014) · Biomarker Research · doi:10.1186/2050-7771-2-4 · Cited by 255
Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy
Rajvanshi, P., Shulman, H. M., Sievers, E. L., & McDonald, G. B. (2002) · Blood · doi:10.1182/blood.v99.7.2310 · Cited by 246
Cooley, S., He, F., Bachanova, V., Vercellotti, G. M., DeFor, T. E., Curtsinger, J. M., Robertson, P., Grzywacz, B., Conlon, K. C., Waldmann, T. A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2018028332 · Cited by 236
Measurable residual disease testing in acute myeloid leukaemia
Hourigan, C. S., Gale, R. P., Gormley, N. J., Ossenkoppele, G. J., & Walter, R. B. (2017) · Leukemia · doi:10.1038/leu.2017.113 · Cited by 235
Morton, L. M., Dores, G. M., Tucker, M. A., Kim, C. J., Onel, K., Gilbert, E. S., Fraumeni, J. F., & Curtis, R. E. (2013) · Blood · doi:10.1182/blood-2012-08-448068 · Cited by 233
Lo-Coco, F. (2004) · Blood · doi:10.1182/blood-2004-04-1550 · Cited by 225
Therapy-Related Myelodysplasia and Acute Myeloid Leukemia
Bhatia, S. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.09.013 · Cited by 219
Oran, B., de Lima, M., Garcia-Manero, G., Thall, P. F., Lin, R., Popat, U., Alousi, A. M., Hosing, C., Giralt, S., Rondon, G., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002544 · Cited by 219
Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy
Carter, J. L., Hege, K., Yang, J., Kalpage, H. A., Su, Y., Edwards, H., Hüttemann, M., Taub, J. W., & Ge, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00361-x · Cited by 218
Ruggeri, A., Labopin, M., Sanz, G., Piemontese, S., Arcese, W., Bacigalupo, A., Blaise, D., Bosi, A., Huang, H., Karakasis, D., et al. (2015) · Leukemia · doi:10.1038/leu.2015.98 · Cited by 216
Walter, R. B., Gyurkocza, B., Storer, B. E., Godwin, C. D., Pagel, J. M., Buckley, S. A., Sorror, M. L., Wood, B. L., Storb, R., Appelbaum, F. R., et al. (2015) · Leukemia · doi:10.1038/leu.2014.173 · Cited by 216
Bowen, D., Groves, M. J., Burnett, A. K., Patel, Y., Allen, C., Green, C., Gale, R. E., Hills, R., Linch, D. C., & on behalf of the Medical Research Council Adult Leukaemia Working Party, U. (2009) · Leukemia · doi:10.1038/leu.2008.173 · Cited by 214
Targeting MCL-1 in hematologic malignancies: Rationale and progress
Wei, A. H., Roberts, A. W., Spencer, A., Rosenberg, A. S., Siegel, D., Walter, R. B., Caenepeel, S., Hughes, P., McIver, Z., Mezzi, K., et al. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100672 · Cited by 210
Fathi, A. T., DiNardo, C. D., Kline, I., Kenvin, L., Gupta, I., Attar, E. C., Stein, E. M., de Botton, S., & for the AG221-C-001 Study Investigators (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.4695 · Cited by 195
Genetic predisposition to hematologic malignancies: management and surveillance
Godley, L. A., & Shimamura, A. (2017) · Blood · doi:10.1182/blood-2017-02-735290 · Cited by 190
Spanholtz, J., Tordoir, M., Eissens, D., Preijers, F., van der Meer, A., Joosten, I., Schaap, N., de Witte, T. M., & Dolstra, H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009221 · Cited by 188
Sekeres, M. A., Guyatt, G., Abel, G., Alibhai, S., Altman, J. K., Buckstein, R., Choe, H., Desai, P., Erba, H., Hourigan, C. S., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001920 · Cited by 188
Jonas, B. A., & Pollyea, D. A. (2019) · Leukemia · doi:10.1038/s41375-019-0612-8 · Cited by 183
How I diagnose and manage individuals at risk for inherited myeloid malignancies
The University of Chicago Hematopoietic Malignancies Cancer Risk Team (2016) · Blood · doi:10.1182/blood-2016-05-670240 · Cited by 182
Morrison, V. A., Rai, K. R., Peterson, B. L., Kolitz, J. E., Elias, L., Appelbaum, F. R., Hines, J. D., Shepherd, L., Larson, R. A., & Schiffer, C. A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.128 · Cited by 176
Battipaglia, G., Labopin, M., Kröger, N., Vitek, A., Afanasyev, B., Hilgendorf, I., Schetelig, J., Ganser, A., Blaise, D., Itälä-Remes, M., et al. (2019) · Blood · doi:10.1182/blood.2019000487 · Cited by 176
Venetoclax for AML: changing the treatment paradigm
Pollyea, D. A., Amaya, M., Strati, P., & Konopleva, M. Y. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000937 · Cited by 174
Weinberg, O. K., Seetharam, M., Ren, L., Seo, K., Ma, L., Merker, J. D., Gotlib, J., Zehnder, J. L., & Arber, D. A. (2009) · Blood · doi:10.1182/blood-2008-10-182782 · Cited by 165
Sense and nonsense of high-dose cytarabine for acute myeloid leukemia
Löwenberg, B. (2013) · Blood · doi:10.1182/blood-2012-07-444851 · Cited by 165
Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1
Dao, T., Pankov, D., Scott, A., Korontsvit, T., Zakhaleva, V., Xu, Y., Xiang, J., Yan, S., de Morais Guerreiro, M. D., Veomett, N., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3349 · Cited by 162
Evaluating measurable residual disease in acute myeloid leukemia
Ravandi, F., Walter, R. B., & Freeman, S. D. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018016378 · Cited by 162
Offman, J., Opelz, G., Doehler, B., Cummins, D., Halil, O., Banner, N. R., Burke, M. M., Sullivan, D., Macpherson, P., & Karran, P. (2004) · Blood · doi:10.1182/blood-2003-11-3938 · Cited by 158
Winters, A. C., Gutman, J. A., Purev, E., Nakic, M., Tobin, J., Chase, S., Kaiser, J., Lyle, L., Boggs, C., Halsema, K. A., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000243 · Cited by 155
Health care utilization and end‐of‐life care for older patients with acute myeloid leukemia
El-Jawahri, A. R., Abel, G. A., Steensma, D. P., LeBlanc, T. W., Fathi, A. T., Graubert, T. A., DeAngelo, D. J., Wadleigh, M., Ballen, K. K., Foster, J., et al. (2015) · Cancer · doi:10.1002/cncr.29430 · Cited by 150
MRD in AML: The Role of New Techniques
Voso, M. T., Ottone, T., Lavorgna, S., Venditti, A., Maurillo, L., Lo‐Coco, F., & Buccisano, F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00655 · Cited by 144
Acute myeloid leukemia: 2021 update on risk‐stratification and management
Estey, E. H. (2020) · American Journal of Hematology · doi:10.1002/ajh.25975 · Cited by 144
Gemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug
Rowe, J. M., & Löwenberg, B. (2013) · Blood · doi:10.1182/blood-2013-03-490482 · Cited by 143
Ostronoff, F., Othus, M. K. D., Lazenby, M., Estey, E. H., Appelbaum, F. R., Evans, A., Godwin, J. E., Gilkes, A., Kopecky, K. J., Burnett, A. K., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.0571 · Cited by 137
Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia
Shih, A. H., Chung, S. S., Dolezal, E. K., Zhang, S.-J., Abdel-Wahab, O. I., Park, C. Y., Nimer, S. D., Levine, R. L., & Klimek, V. M. (2013) · Haematologica · doi:10.3324/haematol.2012.076729 · Cited by 135
Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies
Borot, F., Wang, H., Ma, Y., Jafarov, T., Raza, A., Ali, A. M., & Mukherjee, S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819992116 · Cited by 135
Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia
Sakaguchi, M., Yamaguchi, H., Najima, Y., Usuki, K., Ueki, T., Oh, I., Mori, S., Kawata, E., Uoshima, N., Kobayashi, Y., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018020305 · Cited by 127
Cooley, S., Parham, P., & Miller, J. S. (2018) · Blood · doi:10.1182/blood-2017-08-752170 · Cited by 126
Fianchi, L., Pagano, L., Piciocchi, A., Candoni, A., Gaïdano, G., Breccia, M., Criscuolo, M., Specchia, G., Pogliani, E. M., Maurillo, L., et al. (2015) · American Journal of Hematology · doi:10.1002/ajh.23966 · Cited by 125
Acute Myeloid Leukemia: The Good, the Bad, and the Ugly
Kuykendall, A. T., Duployez, N., Boissel, N., Lancet, J. E., & Welch, J. S. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_199519 · Cited by 124
Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia
Hasserjian, R. P., Steensma, D. P., Graubert, T. A., & Ebert, B. L. (2020) · Blood · doi:10.1182/blood.2019004770 · Cited by 122
Short, N. J., Kantarjian, H. M., Loghavi, S., Huang, X., Qiao, W., Borthakur, G., Kadia, T. M., Daver, N., Ohanian, M., Dinardo, C. D., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30182-0 · Cited by 120
Chimeric Antigen Receptor (CAR) T Cell Therapy in Acute Myeloid Leukemia (AML)
Hofmann, S., Schubert, M., Wang, L., He, B., Neuber, B., Dreger, P., Müller‐Tidow, C., & Schmitt, M. W. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8020200 · Cited by 119
Wang, Y., Xu, Y., Li, S., Liu, J., Xing, Y., Xing, H., Tian, Z., Tang, K., Rao, Q., Wang, M., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0603-7 · Cited by 108
Current status and new treatment approaches in TP53 mutated AML
Hunter, A. M., & Sallman, D. A. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.004 · Cited by 102
Vogler, M., Walter, H. S., & Dyer, M. J. S. (2017) · British Journal of Haematology · doi:10.1111/bjh.14684 · Cited by 99
Eisfeld, A., Kohlschmidt, J., Mrózek, K., Blachly, J. S., Walker, C. J., Nicolet, D., Orwick, S. J., Maharry, S. E., Carroll, A. J., Stone, R. M., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0068-2 · Cited by 99
Drazer, M. W., Kadri, S., SUKHANOVA, M. J., Patil, S., DePersia, A., Feurstein, S. K., Calderon, D. A., Jones, M. F., Weipert, C. M., Daugherty, C. K., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017013037 · Cited by 98
Adoptive cell therapy using engineered natural killer cells
Rezvani, K. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0601-6 · Cited by 96
Vasu, S., He, S., Cheney, C., Gopalakrishnan, B., Mani, R., Lozanski, G., Mo, X., Groh, V., Whitman, S. P., Konopitzky, R., et al. (2016) · Blood · doi:10.1182/blood-2015-11-680546 · Cited by 93
Investigational CD33-targeted therapeutics for acute myeloid leukemia
Walter, R. B. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1452911 · Cited by 87
Becker, P. S., Kantarjian, H. M., Appelbaum, F. R., Petersdorf, S. H., Storer, B. E., Pierce, S. A., Shan, J., Hendrie, P. C., Pagel, J. M., Shustov, A. R., et al. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.08831.x · Cited by 85
Co-occurrence of FLT3-TKD and NPM1 mutations defines a highly favorable prognostic AML group
Boddu, P. C., Kantarjian, H. M., Borthakur, G. M., Kadia, T. M., Daver, N. G., Pierce, S. A., Andreeff, M., Ravandi, F., Cortes, J. E., & Kornblau, S. M. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009019 · Cited by 84
Käyser, S., Benner, A., Thiede, C., Martens, U. M., Huber, J. F. K., Stadtherr, P., Janssen, J. W. G., Röllig, C., Uppenkamp, M. J., Bochtler, T., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.46 · Cited by 83
Devillier, R., Mas, V. M., Gelsi‐Boyer, V., Demur, C., Murati, A., Corre, J., Prébet, T., Bertoli, S., Brecqueville, M., Arnoulet, C., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3460 · Cited by 81
Pratz, K. W., & Levis, M. J. (2016) · Blood · doi:10.1182/blood-2016-09-693648 · Cited by 81
The 2016 WHO classification of acute myeloid leukemia: What the practicing clinician needs to know
Arber, D. A. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.08.002 · Cited by 81
Devillier, R., Gelsi‐Boyer, V., Brecqueville, M., Carbuccia, N., Murati, A., Vey, N., Birnbaum, D., & Mozziconacci, J. (2012) · American Journal of Hematology · doi:10.1002/ajh.23211 · Cited by 75
El-Jawahri, A. R., Nelson-Lowe, M., Vandusen, H. B., Traeger, L. N., Abel, G. A., Greer, J. A., Fathi, A. T., Steensma, D. P., LeBlanc, T. W., Li, Z., et al. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0317 · Cited by 75
Chimeric antigen receptor T-cell therapy for acute myeloid leukemia: how close to reality?
Cummins, K. D., & Gill, S. I. (2019) · Haematologica · doi:10.3324/haematol.2018.208751 · Cited by 75
Will CAR T cell therapy have a role in AML? Promises and pitfalls
Cummins, K. D., & Gill, S. I. (2018) · Seminars in Hematology · doi:10.1053/j.seminhematol.2018.08.008 · Cited by 70
Williams, B. A., Law, A., Hunyadkürti, J., Désilets, S., Leyton, J. V., & Keating, A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081261 · Cited by 61
‘CHIP’ping away at clonal hematopoiesis
Link, D. C., & Walter, M. J. (2016) · Leukemia · doi:10.1038/leu.2016.130 · Cited by 57
Klepin, H. D., Ritchie, E. K., Major-Elechi, B. T., Le‐Rademacher, J. G., Seisler, D. K., Storrick, L., Sanford, B. L., Marcucci, G., Zhao, W., Geyer, S. A., et al. (2019) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2019.10.002 · Cited by 57
Harnessing Natural Killer Cell Antitumor Immunity: From the Bench to Bedside
Woan, K. V., & Miller, J. S. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0404 · Cited by 55
Thomas, X., Elhamri, M., Raffoux, E., Renneville, A., Pautas, C., de Botton, S., de Revel, T., Reman, O., Terré, C., Gardin, C., et al. (2011) · Blood · doi:10.1182/blood-2011-04-349258 · Cited by 53
Gurion, R., Belnik, Y., Gafter‐Gvili, A., Paul, M., Vidal, L., Ben‐Bassat, I., Shpilberg, O., & Raanani, P. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008238.pub3 · Cited by 51
Halpern, A. B., Othus, M. K. D., Huebner, E. M., Scott, B. L., Becker, P. S., Percival, M. M., Hendrie, P. C., Gardner, K. M., Chen, T. L., Buckley, S. A., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0135-8 · Cited by 49
Liu, L., Chang, Y., Xu, L., Zhang, X., Wang, Y., Liu, K., & Huang, X.-J. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.03.030 · Cited by 47
Targeted Elimination of Leukemia Stem Cells; a New Therapeutic Approach in Hemato-Oncology
ten Cate, B., de Bruyn, M., Wei, Y., Bremer, E., Helfrich, W., Mourabet, M. E., El‐Hachem, S., Harrison, J., & Binion, D. G. (2009) · Current Drug Targets · doi:10.2174/138945010790031063 · Cited by 45
Wagner, J., Marquart, J. P., Ruby, J., Lammers, A. J., Mailankody, S., Kaestner, V., & Prasad, V. K. (2018) · BMJ · doi:10.1136/bmj.k668 · Cited by 43
Candoni, A., Marchi, F. D., Zannier, M. E., Lazzarotto, D., Fili, C. C., Dubbini, M. V., Rabassi, N., Toffoletti, E., Lau, B. W., & Fanin, R. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.10.010 · Cited by 38
Tyrosine kinase inhibitors for acute myeloid leukemia: A step toward disease control?
Megías‐Vericat, J. E., Ballesta‐López, O., Barragán, E., Martínez‐Cuadrón, D., & Montesinos, P. (2020) · Blood Reviews · doi:10.1016/j.blre.2020.100675 · Cited by 38
How good are we at predicting the fate of someone with acute myeloid leukaemia?
Estey, E. H., & Gale, R. P. (2017) · Leukemia · doi:10.1038/leu.2017.56 · Cited by 36
Kayastha, N., Wolf, S. P., Locke, S. C., Samsa, G. P., El-Jawahri, A. R., & LeBlanc, T. W. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3973-4 · Cited by 36
Bhatt, V. R. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.04.001 · Cited by 34
Klepin, H. D. (2019) · Blood · doi:10.1182/blood.2019001299 · Cited by 34
Shifting paradigms in the treatment of older adults with AML
LeBlanc, T. W., & Erba, H. P. (2019) · Seminars in Hematology · doi:10.1053/j.seminhematol.2019.02.002 · Cited by 31
Shang, Y., & Zhou, F. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00917 · Cited by 30
The AML–MDS interface—leukemic transformation in myelodysplastic syndromes
Porwit‐MacDonald, A., & Saft, L. (2011) · Journal of Hematopathology · doi:10.1007/s12308-011-0088-6 · Cited by 28
Klimek, V. M. (2013) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32835d82e6 · Cited by 28
Majothi, S., Adams, D., Loke, J. C. T., Stevens, S. P., Wheatley, K., & Wilson, J. S. (2020) · Systematic Reviews · doi:10.1186/s13643-020-01540-1 · Cited by 28
Ball, B. J., & Stein, E. M. (2019) · Haematologica · doi:10.3324/haematol.2018.208587 · Cited by 25
Stoddart, A., Wang, J., Fernald, A. A., Karrison, T. G., Anastasi, J., & Beau, M. M. L. (2013) · Blood · doi:10.1182/blood-2013-05-506568 · Cited by 23
Can we predict responsiveness to hypomethylating agents in AML?
Stomper, J., & Lübbert, M. (2019) · Seminars in Hematology · doi:10.1053/j.seminhematol.2019.02.001 · Cited by 22
Zhou, A.-Q., Han, Q., Song, H., Zi, J., Ma, J., & Ge, Z. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s207425 · Cited by 21
Clonal Hematopoiesis after Induction Chemotherapy for Acute Myeloid Leukemia
Steensma, D. P., & Ebert, B. L. (2018) · New England Journal of Medicine · doi:10.1056/nejme1802610 · Cited by 19
Current treatment strategies for measurable residual disease in patients with acute myeloid leukemia
Percival, M. M., & Estey, E. H. (2019) · Cancer · doi:10.1002/cncr.32354 · Cited by 18
Othus, M. K. D., Sekeres, M. A., Nand, S., Garcia‐Manero, G., Appelbaum, F. R., Erba, H. P., & Estey, E. H. (2018) · Leukemia · doi:10.1038/s41375-018-0275-x · Cited by 13
Loke, J. C. T., Lowe, D. M., Miller, L. J., et al. (2020) · British Journal of Haematology · doi:10.1111/bjh.16708 · Cited by 8
Metadata
- Authors
- Newell, L. F., & Cook, R. J.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2021-10-06
- Volume
- 375
- Pages
- n2026
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W3204486370
- Cited by
- 440
- References
- 177
- FWCI
- 44.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.